← All trials
NCT04648033
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2020
- Primary completion
- Nov 30, 2022
- Completion date
- Feb 28, 2023
- First posted
- Dec 1, 2020
- Last posted
- Dec 1, 2020
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of OxfordLead sponsor
- University of OxfordCollaborator
- Cancer Research UKCollaborator
- University of OxfordOverall official - principal investigator
- National Institute for Health Research, United KingdomCollaborator
- NHS LothianCollaborator
- NHS Research ScotlandCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.